France’s Sanofi buys US hemophilia specialist Bioverativ

PARIS — France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.

The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases.

Sanofi said in a statement that the boards of both companies approved the purchase, and that Sanofi will pay $105 per share in cash for all outstanding shares of Bioverativ. The Waltham, Massachusetts-based company focuses on blood disorders.

Bioverativ said it hopes its Eloctate and Alprolix hemophilia medications can reach a broader market thanks to Sanofi’s global infrastructure.

Sanofi’s strategy in the coming years includes expanding its rare disease portfolio, and hemophilia treatment is considered a growing market.

modified weapon

Sawed-off shotgun seized after Nanaimo RCMP spot well-known offender

12h ago

rainbow eyes

Nanaimo judge hands old growth logging protestor additional jail time

14h ago

Paris Bound

Nanaimo race walker Olivia Lundman qualifies for Paris Olympic Games

16h ago

The Associated Press